Last reviewed · How we verify
induction gemcitabine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
induction gemcitabine (induction gemcitabine) — Radiation Therapy Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| induction gemcitabine TARGET | induction gemcitabine | Radiation Therapy Oncology Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- induction gemcitabine CI watch — RSS
- induction gemcitabine CI watch — Atom
- induction gemcitabine CI watch — JSON
- induction gemcitabine alone — RSS
Cite this brief
Drug Landscape (2026). induction gemcitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/induction-gemcitabine. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab